LM103

Phase 2Biologic

SSuzhou BlueHorse Therapeutics Co., Ltd.

LM103 is one of 87 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerNot yet recruiting

Advanced Solid TumorsNot yet recruiting

Advanced Solid TumoursRecruiting

Non-Small Cell Lung CancerPhase 2

Not yet recruiting

Advanced Solid TumorsPhase 1

Not yet recruiting

Advanced Solid TumoursPhase 1

Recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 3

34 2

Lazcluze

Johnson & Johnson

Phase 3

9 3

TY-9591

TTYK Medicines, Inc

Phase 3

2 4

LM103

SSuzhou BlueHorse Therapeutics Co., Ltd.

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Treatment

GSK

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

PD-1 Inhibitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Solid Tumours

NCT06697665

Q4 2028

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07444437

Phase 2Recruiting

Advanced Melanoma

NCT07310784

Clinical

Trials by Indication[1]

Advanced Solid Tumors3 trials

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Not yet recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 1·NCT05971589·5 enrolled

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Not yet recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 1·NCT05971576·20 enrolled

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Unknown status·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 1·NCT05941936·5 enrolled

Advanced Solid Tumours1 trial

An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

Recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 1·NCT06697665·10 enrolled

Non-Small Cell Lung Cancer1 trial

LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

Not yet recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 2·NCT07444437·45 enrolled

Advanced Melanoma1 trial

A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma

Recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 2·NCT07310784·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for LM103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LM103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LM103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou BlueHorse Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSuzhou BlueHorse Therapeutics Co., Ltd.

LM103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Advanced Solid Tumors3 trials

Advanced Solid Tumours1 trial

Non-Small Cell Lung Cancer1 trial

Advanced Melanoma1 trial

References

Drug Info

Quick Facts

Related News